[ORGANIZATION]
CROWN study
Featured in 1 tracked story · first seen
Situations
Pfizer lorlatinib long‑term lung cancer results
2 clusters · 4 sources · last updated
Latest: Pfizer's lorlatinib cuts intracranial progression risk 94% in ALK‑positive lung cancer
Pfizer presented a seven‑year update of the phase III CROWN trial at the 2026 American Society of Clinical Oncology (ASCO) meeting. The trial compared lorlatinib with crizotinib as first‑line therapy for patients with ad